drugset / Trial / NCT00647959

Fasting Study of Doxycycline Monohydrate Tablets 150 mg and Adoxa Tablets 150 mg

NCT00647959

Phase 1 Completed 36 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's doxycycline monohydrate 150 mg tablets to Par's Adoxa® 150 mg tablets following a single, oral 150 mg (1 x 150 mg) dose administered under fasting conditions.

Timeline

Start
2006-03
Primary completion
2006-03
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 150 mg Oral

Indications

No indication recorded.